The earnings call reflects a strong performance in key growth areas, particularly in the plasma and hemostasis management segments, with significant margin expansion and strategic share buybacks contributing to earnings growth. However, challenges remain in the interventional technologies and overall revenue declined due to portfolio transitions. The company is optimistic about overcoming these challenges with strategic initiatives.

Company Guidance

During the first quarter earnings call for fiscal year 2026, Haemonetics Corporation provided robust guidance, emphasizing several key metrics. The company reported a revenue of $321 million, reflecting a 4% decline due to a $52 million impact from portfolio transitions, but a 13% organic growth excluding CSL. The adjusted EPS grew by 8% to $1.10, driven by strong base business performance and margin expansion. The hospital segment, generating $140 million, saw a 4% increase, with Blood Management Technologies growing by 14%, fueled by a notable 22% rise in hemostasis management. Plasma revenue was $130 million, with a 29% organic growth excluding CSL, bolstered by technology upgrades and a significant software agreement. The company reaffirmed its full-year guidance, expecting a 3% to 6% reported revenue decline, but a 6% to 9% organic growth excluding CSL, with an adjusted operating margin between 26% and 27%. They anticipate a free cash flow of $160 million to $200 million and highlighted improvements in gross margin, reaching 60.8% due to favorable product mix and pricing initiatives.

Strong Organic Revenue Growth

Haemonetics reported a 13% organic revenue growth excluding CSL, driven by strong growth in their base business and margin expansion.

Plasma Segment Performance

The NexSys plasma segment delivered $130 million in revenue, with a 29% organic growth excluding CSL, supported by technology upgrades and a long-term software agreement.

TEG Hemostasis Management Success

Blood Management Technologies grew 14%, led by a 22% growth in hemostasis management, with a 27% growth in the U.S., driven by strong TEG disposable utilization and customer conversions.

Margin Expansion

The adjusted gross margin reached 60.8%, up 550 basis points year-over-year, driven by favorable product mix and a one-time benefit from a plasma software agreement.

Share Buybacks

Recent share buybacks contributed to an 8% growth in adjusted EPS to $1.10.

Haemonetics (HAE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HAE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2026 (Q2)	1.11 / -	1.12	―	―	―
Aug 07, 2025	2026 (Q1)	1.01 / 1.10	1.02	7.84% (+0.08)	―
May 08, 2025	2025 (Q4)	1.22 / 1.24	0.9	37.78% (+0.34)	―
Feb 06, 2025	2025 (Q3)	1.17 / 1.19	1.04	14.42% (+0.15)	―
Nov 07, 2024	2025 (Q2)	1.07 / 1.12	0.99	13.13% (+0.13)	―
Aug 08, 2024	2025 (Q1)	1.00 / 1.02	1.05	-2.86% (-0.03)	―
May 09, 2024	2024 (Q4)	0.89 / 0.90	0.77	16.88% (+0.13)	―
Feb 08, 2024	2024 (Q3)	0.94 / 1.04	0.85	22.35% (+0.19)	―
Nov 02, 2023	2024 (Q2)	0.89 / 0.99	0.83	19.28% (+0.16)	―
Aug 08, 2023	2024 (Q1)	0.72 / 1.05	0.58	81.03% (+0.47)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HAE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$75.77	$55.63	-26.58%
May 08, 2025	$64.25	$68.01	+5.85%
Feb 06, 2025	$71.24	$62.99	-11.58%
Nov 07, 2024	$78.16	$86.53	+10.71%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Haemonetics Corp. (HAE) report earnings?

Haemonetics Corp. (HAE) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Haemonetics Corp. (HAE) earnings time?

Haemonetics Corp. (HAE) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HAE EPS forecast?

HAE EPS forecast for the fiscal quarter 2026 (Q2) is 1.11.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing